Next Generation Sequencing (NGS) in Familial Acute Myeloid Leukemia and Myelodisplastic Syndromes
Next Generation Sequencing (NGS) Approach to Study Known and New Germline Mutations in Familial Acute Myeloid Leukemia and Myelodisplastic Syndromes
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
20 participants
Feb 9, 2017
OBSERVATIONAL
Conditions
Summary
The aim of this study is to look for predisposing mutations in patients and relatives affected by AML and MDS with familial history of myeloid or, less frequently, lymphoid malignancies. Taking advantage of a next generation sequencing (NGS) platform, screening for known and unknown mutations potentially associated with the disease will be done. The screening will be performed on affected and unaffected family members, in order to outline new pedigrees that either validate previous findings or constitute novel discoveries.
Eligibility
Inclusion Criteria7
- Any patient with acute myeloid leukemia (AML) or Myelodisplastic Syndrome (MDS) with:
- a first- or second-degree relative with Acute leukemia or MDS or other myeloid malignancies
- a first- or second-degree relative with Lymphoproliferative neoplasms
- or with clinical features that resemble one of the familial MDS/AML predisposition syndromes:
- History of thrombocytopenia and/or a clinical bleeding propensity (as in RUNX1, ANKRD26 or ETV6 germline mutations)
- Abnormal nails or skin pigmentation, oral leukoplakia, idiopathic pulmonary fibrosis, unexplained liver disease (as in TERT and TERC germline mutations)
- Lymphedema, atypical infections, immune deficiencies (as in GATA2 germline mutations)
Exclusion Criteria3
- any diagnosis other than acute myeloid leukemia (AML) or Myelodisplastic Syndrome (MDS);
- acute myeloid leukemia (AML) or Myelodisplastic Syndrome (MDS) without a first- or second-degree relative with Acute leukemia or MDS or other myeloid malignancies or without a first- or second-degree relative with Lymphoproliferative neoplasms or with clinical features that resemble one of the familial MDS/AML predisposition syndromes;
- unability to sign the informed consent
Interventions
Molecular screening by next generation sequencing (NGS) platform, for known and unknown mutations potentially associated with the disease
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT03058588